Loading...
•
Dec 31, 2024
NeoGenomics Q4 2024 Earnings Report
NeoGenomics reported higher revenue and improved adjusted EBITDA in Q4 2024.
Key Takeaways
NeoGenomics saw an 11% increase in revenue to $172 million in Q4 2024, with an adjusted EBITDA of $12 million, up 27%. Net loss widened to $15 million. Gross profit margin improved to 44.9%, while operational expenses increased due to higher compensation and software support fees.
Revenue grew 11% year-over-year to $172 million.
Net loss increased to $15 million from $14 million in Q4 2023.
Adjusted EBITDA rose 27% to $12 million.
Cash and cash equivalents totaled $387 million.
Forward Guidance
NeoGenomics expects revenue growth of 11-13% in FY 2025, with improved adjusted EBITDA.
Positive Outlook
- Revenue guidance set at $735M to $745M, an increase of up to 13%.
- Adjusted EBITDA projected between $55M and $58M, up 38-45%.
- Continued growth in high-value tests like NGS.
- Strong cash position to support investments and growth.
- Streamlined operational structure for better efficiency.
Challenges Ahead
- Projected net loss between $76M and $85M.
- Higher operating costs expected due to investment in expansion.
- Restructuring activities could impact short-term profitability.
- Macroeconomic factors may affect reimbursement rates.
- Uncertainty in market conditions could impact volume growth.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...